RxDoctor Payments Data

Salvatore Lauria, MD

Cardiovascular Disease · Annapolis, MDNPI 1780748798

Payments from drug & device makers

$10,277in general payments, 2019–2025

Across 390 payments — averaging $26.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • AOP Health US, LLC$695
  • Novartis$610
  • E.r. Squibb & Sons, L.L.C.$575
  • Boehringer Ingelheim$388
  • Johnson & Johnson$382
  • plus $5K from 54 others

What the payments were for

  • Speaking & faculty fees$180%
  • Food & beverage$10,259100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)51$2,870
AOP Health US, LLC1$695
Novartis39$610
E.r. Squibb & Sons, L.L.C.28$575
Boehringer Ingelheim17$388
Johnson & Johnson14$382
Amgen16$350
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)25$345
Novo Nordisk13$309
AstraZeneca(2 entities)17$297
Sanofi-aventis U.S. LLC11$234
Esperion Therapeutics, Inc.7$212
Pfizer11$208
Actelion Pharmaceuticals US, Inc.8$189
Corcept Therapeutics7$135
Acadia Pharmaceuticals Inc8$124
Boston Scientific1$121
Scpharmaceuticals Inc.7$114
UCB, Inc.5$113
Irhythm Technologies, Inc.5$112
Atricure, Inc.5$110
Preventice Services, LLC1$105
Sunovion Pharmaceuticals Inc.6$101
Lilly USA, LLC5$100
Regeneron Healthcare Solutions, Inc.7$97
Kestra Medical Technology Services, Inc.5$88
Lexicon Pharmaceuticals, Inc.4$81
Avanir Pharmaceuticals, Inc.4$73
Merck4$66
Grifols USA, LLC4$65
Medicomp Inc3$63
Kiniksa Pharmaceuticals International, PLC3$62
Shire North American Group Inc3$60
Argenx US, Inc.2$57
Cequr Corporation3$54
Abbott2$48
Alnylam Pharmaceuticals Inc.3$46
Lundbeck LLC3$45
Amarin Pharma, Inc.3$40
Upsher-smith Laboratories LLC1$33
Neurocrine Biosciences, Inc.1$32
Xeris Pharmaceuticals, Inc.2$31
Recordati_rare_diseases_inc.1$26
Eisai Inc.1$25
Dexcom, Inc.1$24
Inspire Medical Systems, Inc.1$24
Kowa Pharmaceuticals America, Inc.2$22
Catalyst Pharmaceuticals, Inc.1$21
Ultragenyx Pharmaceutical Inc.1$21
SK Life Science, Inc.1$20
Takeda Pharmaceuticals U.S.A., Inc.1$20
Greenwich Biosciences, Inc.1$19
Acorda Therapeutics, Inc1$18
Tandem Diabetes Care, Inc.1$18
Astellas Pharma US Inc1$17
EMD Serono, Inc.1$16
Baxter Healthcare1$16
Teva Pharmaceuticals USA, Inc.1$16
Vivus LLC1$16
Bayer1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,277 in reported general payments places this provider in the 75th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$460,681
Medicare patients
1,866
Services billed
4,968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban287$384,090
XareltoRivaroxaban97$142,311
EntrestoSacubitril/Valsartan72$121,040
JardianceEmpagliflozin17$28,293
Repatha SureclickEvolocumab25$24,528
MounjaroTirzepatide24$21,988
FarxigaDapagliflozin Propanediol16$14,366
Metoprolol Succinate465$7,803
Nebivolol Hcl52$5,069
Atorvastatin Calcium346$4,623
Dofetilide15$3,461
Ezetimibe83$3,208
Ranolazine ErRanolazine15$2,867
Rosuvastatin Calcium107$2,780
Nifedipine ErNifedipine55$2,111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$208$384,090287 claims
Johnson & JohnsonXarelto$382$142,31197 claims
NovartisEntresto$610$121,04072 claims
Boehringer IngelheimJardiance$388$28,29317 claims
Lilly USA, LLCMounjaro$100$21,98824 claims
AstraZenecaFarxiga$297$14,36616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Annapolis

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →